VIENNA, Dec. 16, 2024 (GLOBE NEWSWIRE) -- invIOs GmbH, a privately held biotechnology company developing novel therapies for cancer, will participate in JP Morgan week activities in San Francisco, January 13-16, 2025. The company will share updates on its pipeline, including promising developments in its two complementary glioblastoma treatment approaches - a small molecule and a cell therapy, both being advanced in collaboration with Dana-Farber Cancer Institute (DFCI) in Boston.
Peter Llewellyn-Davies, CEO & CFO of invIOs, commented on the collaboration with Dana-Farber Cancer Institute on their cell therapy INV441 and small molecule program INV501, highlighting the strength of their scientific approach and commitment to advancing innovative therapies for challenging solid tumors like glioblastoma. INV501 has shown encouraging preclinical results, including crossing the blood-brain barrier and eliciting robust anti-tumoral immune responses. The company is working closely with DFCI to expand the preclinical data for INV501 and plans to reveal its mode of action in the coming months.
INV501: A novel small molecule candidate that can selectively enhance T cell mediated anti-tumor immune responses. The collaboration with DFCI is progressing well, with the first confirmatory experiments supporting preclinical efficacy in glioblastoma completed. INV501 showed survival benefit in glioblastoma models upon oral administration. Details about the target are planned to be provided in the first quarter of 2025, with data to be presented at the AACR Annual Meeting.
INV441: A tumor-infiltrating lymphocyte (TIL)-based therapy in preclinical development for glioblastoma, originating from invIOs' proprietary EPiC cell enhancement platform. INV441 has shown promising results in glioma models with increased localized anti-tumor immune activity. Following a pre-IND meeting with the U.S. FDA, invIOs is on track to initiate a Phase 1 trial in H2 2025 in collaboration with DFCI.
APN401: Strong clinical data supporting the EPiC platform continues to emerge from the proof-of-concept clinical trial with APN401, based on Cbl-b silenced autologous peripheral immune cells. Earlier findings demonstrated stable disease in two heavily pre-treated patients with advanced solid tumors and validated the therapy's rapid, outpatient manufacturing procedure with a processing time of less than 6 hours. The full data set will provide further insights into the therapy's potential, showing a 38% response rate, which strengthens the foundation for the development of Cbl-b silenced TIL or CAR-T cell therapies (INV441 or INV451). An abstract is being submitted for presentation at a major oncology conference in 2025.
invIOs is a privately held biotech company based in Vienna, Austria, focusing on the discovery and development of novel therapies for cancer. The company leverages deep expertise in immune system activation to develop individualized and targeted approaches against solid tumors, advancing a pipeline of programs encompassing small molecule and cell therapy approaches.
